A Chinese company has expressed interest in developing a biosimilar to Ozempic (semaglutide); Celltrion completed its biologic license application for its omalizumab biosimilar candidate.
A Chinese company has expressed interest in developing a biosimilar to Ozempic (semaglutide), a popular drug used for diabetes and weight loss; Biocon and Mylan are in talks to merge their biosimilar businesses; Celltrion completed its biologic license application (BLA) for its omalizumab biosimilar candidate.
Biosimilar Ozempic on the Horizon?
A report from Reuters found that Chinese drugmaker Hangzhou Jiuyuan Gene Engineering is working on a biosimilar to Novo Nordisk’s semaglutide (Ozempic and Wegovy). Semaglutide has gained a lot of traction around the world in the past couple years, particularly in the US, as a popular treatment for type 2 diabetes and obesity.
The move could pose challenges to the originator manufacturer’s planned expansion into China as patents for Ozempic are not set to expire until 2026. Chinese sales of drug soared in 2023, reaching nearly $700 million; however, the demand is largely driven by people seeking weight loss.
Approval for Hangzhou Jiuyuan Gene Engineering's biosimilar, named Jiyoutai, would make it China's first locally developed biosimilar semaglutide drug. However, Novo Nordisk has expressed concerns about the impact of cheap copies of Ozempic on its business in China, emphasizing the importance of innovation protection to encourage the development of new medicines.
Hangzhou Jiuyuan Gene Engineering conducted a late-stage clinical trial comparing its semaglutide injection with Ozempic. Despite the potential launch of Jiyoutai, the company acknowledged that commercialization would depend on the outcome of Novo Nordisk's patent status on Ozempic.
In related news, Novo also faced challenges with Ozempic supply shortages in Europe, with starter kits unavailable in Germany during the second quarter.
Celltrion Omalizumab Biosimilar Submission
Celltrion USA announced the submission of a BLA for CT-P39, a biosimilar candidate to Xolair (omalizumab). The company is hoping to gain approval for the biosimilar as a treatment for moderate to severe persistent allergic asthma, chronic spontaneous urticaria (CSU), IgE-mediated food allergy, and chronic rhinosinusitis with nasal polyps as well as an interchangeability designation.
The submission included data from a global phase 3 clinical trial assessing CT-P39's efficacy, safety, and pharmacokinetics compared with the reference product in patients with chronic spontaneous urticaria up to week 40.
According to Celltrion, Xolair achieved global market sales of $3.89 billion in 2022. In the US, the compound patent for the product has expired and patents protecting Xolair’s formulation are set to expire in November 2025.
The news comes after Celltrion launched Zymfentra (infliximab-dyyb) in the US as the first and only subcutaneous infliximab product.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.